ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020

Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA OBSV, a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the SVB LEERINK  9^th Annual Global Healthcare Conference taking place February 25-27^th, 2020, in New York City.

Mr. Loumaye's presentation will take place on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time (ET) A live webcast of  the presentation will be available under "Events Calendar" in the investors section of ObsEva's website at www.ObsEva.com

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com

+1 857 972 9347 Office
+1 781 366 5726 Mobile

Attachment

• Press Release in Pdf